|
Post by rak5555 on Aug 19, 2014 8:16:26 GMT -5
A friend sent this to me: newsroom.regeneron.com/releasedetail.cfm?ReleaseID=423433
"The antibody collaboration entered into in November 2007 was scheduled to expire at year-end 2012. As amended, the collaboration will continue at higher levels of funding through 2017. As under the original terms, sanofi-aventis has the exclusive option to co-develop with Regeneron each antibody drug candidate discovered under the collaboration. Development costs for drug candidates co-developed by the parties will be shared, with sanofi-aventis funding development costs up front and Regeneron reimbursing half of the development costs for all collaboration drug candidates from Regeneron's share of future profits from commercialization of collaboration products to the extent future profits are sufficient for this purpose. In the United States, profits will be shared equally, while outside the United States, profits will be split on a pre-determined sliding scale with sanofi-aventis' share ranging from 65 percent to 55 percent.
For any products successfully developed as part of the collaboration, sanofi-aventis will take the lead in commercialization activities and will consolidate the sales. Regeneron will have the right to co-promote any and all collaboration products worldwide. In addition, Regeneron is entitled to receive up to a total of $250 million of sales milestone payments when collaboration products achieve certain aggregate annual ex-U.S. sales levels, starting at $1 billion."
On the day before this deal was signed (Nov 9, 2009), REGN was trading at $18.57. It closed yesterday at $349!
|
|
|
Post by notamnkdmillionaire on Aug 19, 2014 10:52:10 GMT -5
We can all hope this happens with MNKD but MNKD is not REGN. Circumstances and markets are different and MNKD isn't going into this with Wall Street behind it. I do believe once Afrezza starts to sell, many of the crooks on the street will eventually get behind the company.
|
|